Neuroprotective effect of recombinant human erythropoietin on optic nerve injury in rats.
BACKGROUND
Optic nerve injury, caused by retinal and optic nerve diseases, can eventually result in vision loss. To date, few effective treatments have been discovered to restore visual function. Previous studies showed that recombinant human erythropoietin (rhEPO) has a neuroprotective effect on the central nervous system, particularly in nerve injury. In this study, we investigated the effects of rhEPO on axonal regeneration and functional restoration following optic nerve injury. This was done by measuring the expression of growth associated protein 43 (GAP-43), a marker for neuronal regeneration, on the retina and flash-visual evoked potential (F-VEP).


METHODS
Adult Wistar rats were randomly assigned to rhEPO and control (saline) groups. Optic nerve crush injury models were established and rhEPO or saline were immediately injected into the vitreous cavity. The expression of GAP-43 was detected by immunohistochemistry and the F-VEP was measured pre-injury, immediately after injury, 1 week and 2 weeks post-injury.


RESULTS
No detectable staining for GAP-43 was observed in normal retina. In the control group, the level of GAP-43 expression was higher at 1 week post-injury, but decreased at 2 weeks. In the rhEPO group, the level of GAP-43 expression was notably higher at both 1 week and 2 weeks. At each time point post-injury, the expression of GAP-43 in rhEPO group was significantly higher than the control group (P < 0.05). Obvious changes in F-VEP examination were detected immediately after optic nerve injury, including significantly prolonged latency and decreased amplitude of the P1 wave. In the control group, the changes were still obvious at 1 week. The latency was decreased and the amplitude had slightly recovered to 28.23% of the normal value at 2 weeks. In rhEPO group, there was significantly more recovery than the control group at 1 week and 2 weeks post-injury (P < 0.05). The latency most close to the normal level and the amplitude had recovered to 65.51% of the normal value at 2 weeks.


CONCLUSIONS
rhEPO can prolong the expression of GAP-43 and increase its intensity after optic nerve injury, thereby promoting neural repair and axonal regeneration. Under the protection of rhEPO, the conduction velocity of the optic nerve recovered significantly. Therefore, rhEPO has neuroprotective effects on the optic nerve and promotes functional restoration of the optic nerve.
Wang
Hui
H
Department of Ophthalmology, First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Liu
Zhe-li
ZL
Zhuang
Xiao-tong
XT
Wang
Min-fang
MF
Xu
Li
L
D000818:Animals; D004921:Erythropoietin / Q000494:pharmacology* / Q000627:therapeutic use; D005074:Evoked Potentials, Visual / Q000187:drug effects; D019922:GAP-43 Protein / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D009900:Optic Nerve / Q000187:drug effects*; D020221:Optic Nerve Injuries / Q000188:drug therapy; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D012160:Retina / Q000187:drug effects* / Q000378:metabolism
D019922:GAP-43 Protein; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D004921:Erythropoietin